JW Pharmaceutical (XKRX:001067) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:001067 JW Pharmaceutical XKRX:001067
86 GF Score
Price ₩48,400.00
GF Value ₩54,245.56
Valuation Modestly Undervalued
View Full Analysis

What is JW Pharmaceutical Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XKRX:001067
86GF Score
JW Pharmaceutical XKRX:001067
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JW Pharmaceutical (XKRX:001067) Overvalued in 2026?

Based on GuruFocus' analysis, JW Pharmaceutical stock appears to be undervalued. The current stock price of ₩48,400.00 is trading 10.8% below its estimated GF Value™ of ₩54,245.56. GuruFocus considers JW Pharmaceutical to be Modestly Undervalued.

Key valuation signals for XKRX:001067:

  • Dividends Received:
  • GF Value™: ₩54,245.56 vs. price of ₩48,400.00 (10.8% below fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the XKRX:001067 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JW Pharmaceutical Business Description

Address 2477, Nambusunhwan-ro, Seocho-gu, KOR
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
86GF Score

Get the complete analysis for XKRX:001067

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩48,400.00
Price
₩54,245.56
GF Value